NAFLD / MASLD Supplements With Evidence: What Actually Works

Why Supplements Get Attention for Fatty Liver Disease

Metabolic-associated steatotic liver disease (MASLD, formerly NAFLD) affects roughly one in four adults in the United States, yet until resmetirom received FDA approval in March 2024, no drug was specifically indicated for this condition. That gap between disease burden and approved pharmacotherapy drove patients and clinicians toward supplements with plausible hepatoprotective mechanisms.

The renaming from NAFLD to MASLD in 2023 by a multi-society Delphi consensus reflected the metabolic drivers of the disease: insulin resistance, dyslipidemia, and visceral adiposity. Supplements that target oxidative stress, lipid metabolism, or insulin sensitivity have biological rationale. The problem is that biological rationale and clinical proof are different things.

Weight loss of 7-10% of total body weight remains the single most effective intervention, resolving steatohepatitis in up to 90% of patients who achieve it. The AASLD 2023 practice guidance explicitly states that lifestyle modification is first-line therapy. Supplements are adjuncts, not replacements. This distinction matters because patients who rely on pills instead of behavioral change may delay the intervention that works best.

The sections below rank supplements by strength of evidence, starting with vitamin E, which has the largest and most rigorous trial data.

Vitamin E: The Strongest Supplement Evidence in NASH

Vitamin E (alpha-tocopherol) at 800 IU/day is the most extensively studied supplement for non-alcoholic steatohepatitis. The PIVENS trial (N=247), published in the New England Journal of Medicine in 2010, randomized non-diabetic adults with biopsy-confirmed NASH to vitamin E 800 IU/day, pioglitazone 30 mg/day, or placebo for 96 weeks. The primary outcome, improvement in histological features of NASH by at least two points with no worsening of fibrosis, was met by 43% of the vitamin E group versus 19% of placebo (P=0.001).

That result was specific to patients without diabetes. The AASLD practice guidance recommends vitamin E 800 IU/day as a pharmacologic option for non-diabetic adults with biopsy-proven NASH. The recommendation does not extend to diabetic patients, patients without biopsy confirmation, or those with simple steatosis (NAFL without inflammation).

A 2023 meta-analysis of 15 RCTs (N=1,317) confirmed that vitamin E significantly reduced ALT (weighted mean difference: -10.8 U/L) and improved steatosis and lobular inflammation on histology. Fibrosis improvement was not statistically significant across pooled data.

Safety is a real consideration. The SELECT trial (N=35,533) found that vitamin E 400 IU/day increased the absolute risk of prostate cancer by 1.6 per 1,000 person-years in healthy men (HR 1.17 to 99% CI 1.004-1.36). A meta-analysis by Miller et al. suggested increased all-cause mortality at doses exceeding 400 IU/day, although this finding has been debated. Clinicians must weigh these risks against the hepatic benefit, especially in male patients.

Omega-3 Fatty Acids: Reducing Liver Fat, Not Fibrosis

Omega-3 polyunsaturated fatty acids (EPA and DHA) reduce hepatic triglyceride content through activation of PPAR-alpha and suppression of SREBP-1c. The clinical question is whether this biochemical effect translates to meaningful histological improvement.

A 2016 Cochrane review of omega-3 supplementation in NAFLD found that it reduced liver fat on imaging, but the evidence was rated low to very low certainty due to small sample sizes and methodological limitations. More recent data have been more encouraging. A 2020 meta-analysis of 22 RCTs (N=1,366) reported that omega-3 supplementation significantly decreased hepatic fat fraction (standardized mean difference: -0.97), along with reductions in ALT, AST, triglycerides, and total cholesterol.

Dose matters. Trials using less than 2 g/day of combined EPA+DHA generally showed weaker or null effects. The WELCOME trial used DHA+EPA at 4 g/day for 15-18 months and demonstrated a reduction in liver fat percentage by MRS from 21.8% to 15.3%, though this difference did not reach statistical significance for the primary endpoint of fibrosis change.

For patients already on statin therapy for dyslipidemia, adding prescription-strength omega-3 (icosapent ethyl 4 g/day, as studied in REDUCE-IT) addresses cardiovascular risk, the leading cause of death in MASLD patients, while potentially providing hepatic benefit. The AASLD does not specifically recommend omega-3 for NASH treatment, but does acknowledge the cardiovascular rationale given that heart disease kills more MASLD patients than liver disease does.

A reasonable evidence-based dose is 2-4 g/day of combined EPA+DHA from pharmaceutical-grade fish oil or prescription formulations.

Silymarin (Milk Thistle): Popular but Incompletely Proven

Silymarin, a flavonolignan complex extracted from Silybum marianum, is the most commonly purchased liver supplement in the United States. Its proposed mechanisms include antioxidant activity, anti-inflammatory effects via NF-kB inhibition, and antifibrotic properties in hepatic stellate cells.

The clinical data are mixed but not discouraging. A 2017 RCT by Solhi et al. randomized 64 NAFLD patients to silymarin 420 mg/day or placebo for 8 weeks and found significant reductions in ALT and AST. A larger Iranian RCT (N=138) using silymarin 700 mg/day for 48 weeks reported improvements in hepatic steatosis on ultrasound along with ALT normalization. Neither trial included paired liver biopsies, which limits conclusions about fibrosis.

The SyNCH trial, a phase IIb NIDDK-funded study (N=154), tested a higher-bioavailability silymarin preparation (silybin-phosphatidylcholine) at 700 mg TID for 48 weeks in patients with NASH. The primary endpoint (reduction in NAS score by 2 points or more) was not met, though a dose-response trend was observed.

Silymarin is generally safe, with GI side effects (bloating, diarrhea) being the most common complaint. Drug interactions are minimal, though silymarin may inhibit CYP3A4 and UGT1A1 at high doses, which could affect statin and immunosuppressant metabolism.

The bottom line: silymarin may improve transaminases in MASLD, but hard histological endpoints remain unproven. At 420-700 mg/day, it is a low-risk adjunct but not a substitute for weight loss or evidence-based pharmacotherapy.

Berberine: Insulin Sensitizer With Hepatic Effects

Berberine, an isoquinoline alkaloid found in goldenseal and barberry, activates AMP-activated protein kinase (AMPK), the same pathway targeted by metformin. This mechanism reduces hepatic gluconeogenesis, improves insulin sensitivity, and decreases lipogenesis.

A 2020 RCT by Yan et al. randomized 184 NAFLD patients to berberine 500 mg TID, pioglitazone, or lifestyle modification alone for 16 weeks. Berberine reduced hepatic fat content by 17.4% (measured by CT), compared to 10.4% in the lifestyle-only group. ALT and triglycerides also decreased significantly.

A 2024 meta-analysis of 10 RCTs (N=811) found that berberine significantly reduced ALT (WMD: -9.1 U/L), AST (WMD: -7.3 U/L), triglycerides, and HOMA-IR compared to controls. The effect on hepatic steatosis on imaging was consistent across studies, but no trial included biopsy endpoints.

The main limitation is that all large berberine-NAFLD trials come from Chinese populations, raising questions about generalizability. GI side effects (diarrhea, constipation, abdominal discomfort) occur in 10-15% of patients. Berberine also inhibits CYP2D6, CYP3A4, and CYP2C9, creating potential interactions with statins, cyclosporine, and warfarin.

A typical dose is 500 mg two to three times daily, taken with meals to reduce GI effects. Given the metabolic profile of most MASLD patients (insulin resistance, dyslipidemia), berberine's multi-target activity is mechanistically appealing, but more diverse population data and biopsy-based outcomes are needed before it can be broadly recommended.

Resveratrol: Small Effects, Small Trials

Resveratrol, a polyphenol found in grape skin and red wine, activates SIRT1 and AMPK and has shown hepatoprotective effects in animal models of steatosis. The human data are less impressive.

A 2020 meta-analysis by Elgebaly et al. pooled four RCTs (N=158) and found no significant effect of resveratrol on ALT, AST, hepatic steatosis, or insulin resistance in NAFLD patients. Individual trials used doses ranging from 150 mg to 3 to 000 mg daily for 8-24 weeks.

One 2014 RCT by Faghihzadeh et al. (N=50) did find that resveratrol 500 mg/day for 12 weeks reduced ALT and hepatic steatosis grade, but the small sample size limits confidence. Bioavailability is a persistent concern: oral resveratrol undergoes extensive first-pass metabolism, and plasma levels vary widely between individuals.

At present, resveratrol cannot be recommended for MASLD based on available evidence. Patients who enjoy moderate red wine consumption do not need to stop for liver reasons (assuming no alcohol-related liver disease), but supplementation specifically for fatty liver is not supported by the data.

Other Supplements: Brief Evidence Summaries

Several additional compounds have been studied in NAFLD/MASLD with varying levels of rigor.

Probiotics and synbiotics. A 2019 meta-analysis of 25 RCTs (N=1,309) found that probiotics significantly reduced ALT (WMD: -11.3 U/L), hepatic steatosis, and HOMA-IR. The gut-liver axis is a plausible mechanism, but strain specificity is poorly defined. Multi-strain formulations (particularly those containing Lactobacillus and Bifidobacterium species) showed the most consistent benefit.

Curcumin (turmeric extract). A 2019 RCT by Rahmani et al. (N=80) found that curcumin 500 mg/day (as phytosomal preparation for better bioavailability) reduced hepatic fat content by ultrasound and lowered ALT over 8 weeks. Larger trials with histological endpoints are absent.

Coffee. Not a supplement, but epidemiological data are consistent and worth noting. A 2017 meta-analysis of 11 studies found that drinking 2 or more cups of coffee daily was associated with a 44% reduced odds of liver fibrosis in NAFLD patients (OR 0.56 to 95% CI 0.40-0.77). This appears related to chlorogenic acid and caffeine's anti-fibrotic effects. The AASLD acknowledges this association without making a formal recommendation.

N-acetylcysteine (NAC). Limited to small pilot studies in NAFLD. A 2018 RCT (N=60) found that NAC 600 mg BID for 3 months reduced ALT and improved ultrasound steatosis scores, but the trial was single-center and open-label.

How to Prioritize: A Clinical Decision Framework

The choice of supplement should reflect disease stage, comorbidities, and what the patient is already doing for weight management.

For patients with biopsy-proven NASH/MASH without diabetes, vitamin E 800 IU/day has the strongest evidence and is supported by AASLD guidance. For patients with MASLD and cardiovascular risk factors (which includes most patients, given that heart disease is their leading cause of death), omega-3 at 2-4 g/day addresses both hepatic and cardiac endpoints.

For patients with insulin resistance and elevated triglycerides who cannot tolerate metformin or are not candidates for GLP-1 receptor agonists, berberine 500 mg TID is a reasonable consideration, with the caveat that evidence comes primarily from Asian populations.

Silymarin is a low-risk option for patients who request a "liver supplement." Its safety profile is clean, and it may improve transaminases, even if fibrosis benefit remains unproven. Probiotics are similarly low-risk and may offer benefit through the gut-liver axis.

None of these supplements should delay or replace weight loss, which remains the most effective therapy. As Dr. Zobair Younossi, chairman of the Global NASH Council, stated: "Weight loss of 10% is the gold standard. Everything else is compared to it." The FLINT trial and PIVENS trial results, while encouraging for pharmacotherapy and vitamin E respectively, produced histological improvement rates below what 10% weight loss achieves.

Patients already on resmetirom (Rezdiffra) or a GLP-1 receptor agonist for metabolic indications should discuss supplement use with their prescriber, as interaction data with multiple concurrent hepatoprotective agents is limited. The MAESTRO-NASH trial (N=966) that led to resmetirom's approval did not study concurrent supplement use.

Supplements to Avoid in MASLD

Not all supplements are neutral. Patients with fatty liver disease should avoid high-dose vitamin A (hepatotoxic above 25 to 000 IU/day), kava (associated with severe hepatotoxicity in case series), and green tea extract at concentrated doses above 800 mg EGCG daily, which the NCCIH has linked to liver injury in clinical trial participants. Proprietary "liver detox" blends with undisclosed ingredient doses are unregulated and pose unpredictable risk to an already stressed organ.

Patients taking statins for dyslipidemia, which is appropriate for the cardiovascular risk profile of most MASLD patients, should avoid red yeast rice supplements that contain monacolin K (identical to lovastatin), as this creates unmonitored statin-on-statin dosing. The FDA has warned about variable monacolin K content in red yeast rice products.

The safest approach: disclose every supplement to the treating hepatologist or gastroenterologist and check for CYP450 interactions before combining supplements with prescription medications.